NCT05144867
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Radiation Therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: 
Exclusions: Patient has greater than 3 brain metastasis; Patient has tumors that have a maximum diameter greater than 4cm on MRI
https://ClinicalTrials.gov/show/NCT05144867